Impaired fasting glucose and major adverse cardiovascular events by hypertension and dyslipidemia status: the Golestan cohort study

[1]  H. Huikuri,et al.  Prediabetes and Risk for Cardiac Death Among Patients With Coronary Artery Disease: The ARTEMIS Study , 2019, Diabetes Care.

[2]  P. Glasziou,et al.  Legacy effects of statins on cardiovascular and all-cause mortality: a meta-analysis , 2018, BMJ Open.

[3]  Björn Eliasson,et al.  Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes , 2018, The New England journal of medicine.

[4]  Yuan-Lin Guo,et al.  Impacts of Prediabetes Mellitus Alone or Plus Hypertension on the Coronary Severity and Cardiovascular Outcomes , 2018, Hypertension.

[5]  P. Kronsbein,et al.  Diabetes primary prevention program: New insights from data analysis of recruitment period , 2018, Diabetes/metabolism research and reviews.

[6]  A. Jayyousi,et al.  Macrovascular Complications in Patients with Diabetes and Prediabetes , 2017, BioMed research international.

[7]  Dai Lin,et al.  Antidiabetic Micro-/Nanoaggregates from Ge-Gen-Qin-Lian-Tang Decoction Increase Absorption of Baicalin and Cellular Antioxidant Activity In Vitro , 2017, BioMed research international.

[8]  T. Ohkubo,et al.  Hypertension with diabetes mellitus: significance from an epidemiological perspective for Japanese , 2017, Hypertension Research.

[9]  F. Ismail-Beigi,et al.  Predictive and explanatory factors of cardiovascular disease in people with adequately controlled type 2 diabetes , 2017, European journal of preventive cardiology.

[10]  R. Chou,et al.  Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force , 2016, JAMA.

[11]  Haider J. Warraich,et al.  Dyslipidemia in diabetes mellitus and cardiovascular disease. , 2017, Cardiovascular endocrinology.

[12]  J. Pankow,et al.  Comparative Prognostic Performance of Definitions of Prediabetes in the Atherosclerosis Risk in Communities (ARIC) Study , 2016, The lancet. Diabetes & endocrinology.

[13]  E. Sahna,et al.  Pattern of Lipid Profi le Abnormality in Subjects with Prediabetes , 2017 .

[14]  2. Classification and Diagnosis of Diabetes , 2016, Diabetes Care.

[15]  Yuli Huang,et al.  Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis , 2016, British Medical Journal.

[16]  Ian Blazina,et al.  Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force. , 2016, JAMA.

[17]  Jessica L. Hurtubise,et al.  The Different Facets of Dyslipidemia and Hypertension in Atherosclerosis , 2016, Current Atherosclerosis Reports.

[18]  Weijian Huang,et al.  Serum Markers of Endothelial Dysfunction and Inflammation Increase in Hypertension with Prediabetes Mellitus. , 2016, Genetic testing and molecular biomarkers.

[19]  T. K. Kamble,et al.  Lipid Profile in Prediabetes. , 2016, The Journal of the Association of Physicians of India.

[20]  L. Mayans.  Metabolic Syndrome: Insulin Resistance and Prediabetes. , 2015, FP essentials.

[21]  Weiqing Wang,et al.  Effects of Prediabetes Mellitus Alone or Plus Hypertension on Subsequent Occurrence of Cardiovascular Disease and Diabetes Mellitus: Longitudinal Study , 2015, Hypertension.

[22]  A. Sharrett,et al.  Diabetes Mellitus, Prediabetes, and Incidence of Subclinical Myocardial Damage , 2014, Circulation.

[23]  Jackson T. Wright,et al.  2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). , 2014, JAMA.

[24]  T. Mäkikallio,et al.  Impaired Fasting Plasma Glucose and Type 2 Diabetes Are Related to the Risk of Out-of-Hospital Sudden Cardiac Death and All-Cause Mortality , 2013, Diabetes Care.

[25]  V. Montori,et al.  The association of hypertriglyceridemia with cardiovascular events and pancreatitis: a systematic review and meta-analysis , 2012, BMC Endocrine Disorders.

[26]  P. Jain,et al.  LIPITENSION: Interplay between dyslipidemia and hypertension , 2012, Indian journal of endocrinology and metabolism.

[27]  P. Iozzo,et al.  Pathophysiology of prediabetes. , 2011, The Medical clinics of North America.

[28]  Reza Malekzadeh,et al.  Verbal Autopsy: Reliability and Validity Estimates for Causes of Death in the Golestan Cohort Study in Iran , 2010, PloS one.

[29]  E. Ford,et al.  Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. , 2010, Journal of the American College of Cardiology.

[30]  R. Malekzadeh,et al.  Cohort Profile: The Golestan Cohort Study--a prospective study of oesophageal cancer in northern Iran. , 2010, International journal of epidemiology.

[31]  P. Libby,et al.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.

[32]  F. Hu,et al.  Fasting and postchallenge hyperglycemia and risk of cardiovascular disease in Chinese: the Chin-Shan Community Cardiovascular Cohort study. , 2008, American heart journal.

[33]  J. Shaw,et al.  Risk of Cardiovascular and All-Cause Mortality in Individuals With Diabetes Mellitus, Impaired Fasting Glucose, and Impaired Glucose Tolerance: The Australian Diabetes, Obesity, and Lifestyle Study (AusDiab) , 2007, Circulation.

[34]  B. Howard,et al.  Prehypertension, Diabetes, and Cardiovascular Disease Risk in a Population-Based Sample: The Strong Heart Study , 2006, Hypertension.

[35]  D. Bennett,et al.  Blood pressure and cardiovascular disease in the Asia Pacific region. , 2003, Journal of hypertension.

[36]  R. Norton,et al.  Blood pressure and cardiovascular disease in the Asia Pacific region , 2003 .

[37]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[38]  D. Lefer.  Statins as potent antiinflammatory drugs. , 2002, Circulation.

[39]  E. Feskens,et al.  Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. , 2001, Archives of internal medicine.

[40]  E. Feskens,et al.  Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria , 1999, The Lancet.

[41]  J. Tardif,et al.  Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. , 1999, Circulation.

[42]  A Sekikawa,et al.  Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. , 1999, Diabetes care.

[43]  D. Waters,et al.  Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. , 1995, Circulation.

[44]  S. Haffner,et al.  Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? , 1990, JAMA.

[45]  BOULIN,et al.  Classification and Diagnosis of Diabetes. , 2022, Primary care.